Morgan Stanley analyst Mark Purcell raised the firm’s price target on AstraZeneca to 12,700 GBp from 12,600 GBp and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- 5 Healthcare Stocks to Buy Now, According to Analysts – August 2023
- Sanofi says CDC panel unanimously recommends use of Beyfortus for infants
- AstraZeneca and Sanofi RSV drug wins support of CDC panel, Bloomberg says
- Zentalis appoints Freeman as Chief Strategy Officer
- AstraZeneca (AZN) Announces Q3 Dividend: Read On for Important Dates